Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
Fuel Price Spike Drives Surge in Used EV Sales in Europe- What an expert on the gut microbiome eats in a day
- NASA wants to build a base on the Moon by the 2030s – how and why it plans to build up to a long-term lunar presence
- Display of Netanyahu's severed head 'incites public to murder PM', Likud says in official complaint
- What is IDF's view on pontential long-term occupation of southern Lebanon?
- Misremembering might actually be a sign your memory is working optimally
- Shah Capital pushes for Novavax sale, warns of proxy fight
- 2026 Golden Globes live updates: Red carpet arrivals will kick off the night; Nikki Glaser set to host
- Which European countries have mandatory or voluntary military service
